Short-course pembrolizumab and continuous afatinib therapy for recurrent or metastatic head and neck squamous cell carcinoma: a real-world data analysis

[1]  J. Machiels,et al.  658MO Pembrolizumab (pembro) vs standard-of-care (SOC) in previously treated recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC): 6-year follow-up of KEYNOTE-040 , 2022, Annals of Oncology.

[2]  D. Shin,et al.  A phase II trial of pembrolizumab and cabozantinib in patients (pts) with recurrent metastatic head and neck squamous cell carcinoma (RMHNSCC). , 2022, Journal of Clinical Oncology.

[3]  Joaquim M Farinhas,et al.  Phase II multi-institutional clinical trial result of concurrent cetuximab and nivolumab in recurrent and/or metastatic head and neck squamous cell carcinoma. , 2022, Clinical cancer research : an official journal of the American Association for Cancer Research.

[4]  Yueh-Fu Fang,et al.  Comparative Effectiveness and Safety of Standard-Dose and Low-Dose Pembrolizumab in Patients with Non-Small-Cell Lung Cancer: A Multi-Institutional Cohort Study in Taiwan , 2022, Cancers.

[5]  Chun-Nan Chen,et al.  Afatinib and Pembrolizumab for Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (ALPHA Study): A Phase II Study with Biomarker Analysis , 2021, Clinical cancer research : an official journal of the American Association for Cancer Research.

[6]  Sc Hsieh,et al.  Real-world results of immune checkpoint inhibitors from the Taiwan National Health Insurance Registration System. , 2021, European review for medical and pharmacological sciences.

[7]  S. Lippman,et al.  Pembrolizumab plus cetuximab in patients with recurrent or metastatic head and neck squamous cell carcinoma: an open-label, multi-arm, non-randomised, multicentre, phase 2 trial. , 2021, The Lancet. Oncology.

[8]  S. Sleijfer,et al.  Early discontinuation of PD-1 blockade upon achieving a complete or partial response in patients with advanced melanoma: the multicentre prospective Safe Stop trial , 2021, BMC Cancer.

[9]  R. Motzer,et al.  Phase IB/II Trial of Lenvatinib Plus Pembrolizumab in Patients With Advanced Renal Cell Carcinoma, Endometrial Cancer, and Other Selected Advanced Solid Tumors , 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  Hung-Ming Wang,et al.  Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study , 2019, The Lancet.

[11]  O. V. Matorin,et al.  Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study , 2019, The Lancet.

[12]  P. Jänne,et al.  A High-Throughput Immune-Oncology Screen Identifies EGFR Inhibitors as Potent Enhancers of Antigen-Specific Cytotoxic T-lymphocyte Tumor Cell Killing , 2018, Cancer Immunology Research.

[13]  Claudimar Pereira da Veiga,et al.  Concern over cost of and access to cancer treatments: A meta-narrative review of nivolumab and pembrolizumab studies. , 2018, Critical reviews in oncology/hematology.

[14]  K. Harrington,et al.  Nivolumab vs investigator's choice in recurrent or metastatic squamous cell carcinoma of the head and neck: 2-year long-term survival update of CheckMate 141 with analyses by tumor PD-L1 expression. , 2018, Oral oncology.

[15]  Ruud H. Brakenhoff,et al.  The molecular landscape of head and neck cancer , 2018, Nature Reviews Cancer.

[16]  James R. Anderson,et al.  Durable Complete Response After Discontinuation of Pembrolizumab in Patients With Metastatic Melanoma. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  R. Ferris,et al.  Oncogenic growth factor signaling mediating tumor escape from cellular immunity. , 2017, Current opinion in immunology.

[18]  I. Mellman,et al.  Elements of cancer immunity and the cancer–immune set point , 2017, Nature.

[19]  Jun Yao,et al.  Glycosylation and stabilization of programmed death ligand-1 suppresses T-cell activity , 2016, Nature Communications.

[20]  Erich P Huang,et al.  RECIST 1.1-Update and clarification: From the RECIST committee. , 2016, European journal of cancer.

[21]  J. Radford.  Nivolumab for recurrent squamous-cell carcinoma of the head and neck , 2016, BDJ.

[22]  Hongyang Wang,et al.  EGFR has a tumor-promoting role in liver macrophages during hepatocellular carcinoma formation , 2014, Nature Cell Biology.

[23]  David C. Smith,et al.  Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[24]  D. Schadendorf,et al.  Improved survival with ipilimumab in patients with metastatic melanoma. , 2010, The New England journal of medicine.